Agios Pharmaceuticals, Inc. (AGIO) Stock Price & Analysis

Agios Pharmaceuticals, Inc. (AGIO) rose 0.22% to USD 36.36 as of July 25, 2026 at 02:22 UTC, according to Nexqual real-time market data.

AGIO last closed at USD 36.28; the session ranged USD 35.61–36.68 on volume of 862,146 shares. Market capitalization is $2.16B, with a 52-week range of USD 22.24–46 (NMS). Source: Nexqual, July 25, 2026 at 02:22 UTC.

Key Statistics (as of July 25, 2026 at 02:22 UTC)

Technical Analysis (AGIO)

Nexqual's technical model rates AGIO "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 02:22 UTC.

Analyst Ratings (AGIO)

Wall Street analysts rate AGIO "Buy" based on 8 analysts, with a mean price target of USD 42.38 (range USD 31–59), per Nexqual as of July 25, 2026 at 02:22 UTC.

Earnings (AGIO)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 02:22 UTC.

Financials & Fundamentals (AGIO)

Source: Nexqual, July 25, 2026 at 02:22 UTC.

Financial Health Score (AGIO)

Nexqual rates Agios Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:22 UTC.

Ownership (AGIO)

Source: Nexqual, July 25, 2026 at 02:22 UTC.

Leadership (AGIO)

Agios Pharmaceuticals, Inc. is led by Brian M. Goff (age 56), CEO & Director, per Nexqual as of July 25, 2026 at 02:22 UTC.

Major Backers & Investors (AGIO)

Notable institutional backers of Agios Pharmaceuticals, Inc. include Farallon Capital Management LLC, Armistice Capital, LLC, Erste Asset Management GmbH, according to Nexqual as of July 25, 2026 at 02:22 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 02:22 UTC.

From Agios Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We will have a pre-supplemental New Drug Application, or sNDA, meeting with the FDA in the first quarter of 2026 and intend to submit a U.S. marketing application for mitapivat in sickle cell disease, or SCD, following that engagement.
• Intellectual Property Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates and our core technologies, including novel biomarker and diagnostic discoveries, and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary or intellectual property rights.
• We also rely on confidential information, know-how, in-licensing opportunities and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
• We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, third-party service providers, scientific advisors, employees and consultants, and by invention assignment agreements with our employees.

Partnerships

• Revenues associated with the NewBridge Agreement, the Avanzanite Agreement and the for charge portion of our global managed access program are included in the rest of world product revenue line within R esults of O perations .
• Also, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we are developing a product candidate, AG-236, for the potential treatment of patients with PV.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:22 UTC. This page is informational and not investment advice.